Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darinaparsin - Solasia Pharma

Drug Profile

Darinaparsin - Solasia Pharma

Alternative Names: SP-02; SP-02L; Zinapar; ZIO-101

Latest Information Update: 19 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
  • Developer Solasia Pharma; ZIOPHARM Oncology
  • Class Antineoplastics; Arsenicals; Oligopeptides; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell division inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Peripheral T-cell lymphoma
  • Preclinical Haematological malignancies
  • Discontinued Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 18 Sep 2019 Darinaparsin - Solasia Pharma is available for licensing in (excluding Asia) as of 18 Sep 2019. www.solasia.co.jp
  • 27 Feb 2019 Solasia plans a pivotal trial for Peripheral T-cell Lymphoma in China (Solasia pipeline, February 2019)
  • 13 Feb 2019 Phase-II clinical trials in Peripheral T-cell lymphoma in China (IV) (Solasia pipeline, February 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top